Amicus Therapeutics (NASDAQ:FOLD) Sets New 52-Week Low - Should You Sell?

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report)'s share price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $8.52 and last traded at $8.60, with a volume of 107904 shares changing hands. The stock had previously closed at $8.69.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on FOLD. Morgan Stanley restated an "equal weight" rating and set a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $16.75.

Remove Ads

Amicus Therapeutics Stock Performance

The company has a quick ratio of 2.42, a current ratio of 3.39 and a debt-to-equity ratio of 2.01. The business has a 50 day moving average price of $9.28 and a 200 day moving average price of $9.97. The stock has a market cap of $2.59 billion, a P/E ratio of -46.83, a PEG ratio of 1.51 and a beta of 0.69.

Institutional Trading of Amicus Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. HealthInvest Partners AB increased its stake in Amicus Therapeutics by 18.6% in the 4th quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company's stock worth $3,076,000 after buying an additional 51,368 shares during the period. Wellington Management Group LLP grew its stake in Amicus Therapeutics by 13.5% in the 3rd quarter. Wellington Management Group LLP now owns 23,964,044 shares of the biopharmaceutical company's stock worth $255,936,000 after acquiring an additional 2,856,101 shares in the last quarter. Tempus Wealth Planning LLC purchased a new position in shares of Amicus Therapeutics during the fourth quarter worth approximately $259,000. Neo Ivy Capital Management bought a new stake in shares of Amicus Therapeutics during the third quarter valued at approximately $702,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Amicus Therapeutics by 35.7% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 302,536 shares of the biopharmaceutical company's stock valued at $2,850,000 after purchasing an additional 79,602 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.